[Risk and management of anti-vitamin K in the elderly].
VKA are underused in elderly patients with thrombo-embolic disease, mainly because of their increased risk of bleeding. However, in most cases, evaluation of this risk versus the efficacy in prevention of thrombo-embolic events, should not lead to a therapeutic abstention. The use of VKA in frail elderly patients requires a specific clinical assessment before and during treatment. Moreover, initiation and management of VKA therapy offers some specificities in older patients.
Pautas
Eric
E
Unité gériatrique aiguë, hôpital Charles-Foix (AP-HP), Ivry-sur-Seine, France. eric.pautas@cfx.aphp.fr
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D014812:Vitamin K